Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab
Michelle Long Schoettler(Children's Healthcare of Atlanta), Franco Locatelli(Bambino Gesù Children's Hospital), Christopher C. Dvorak(University of California, San Francisco), Min Qin(National Institutes of Health), Sonali Chaudhury(Northwestern University), Aviva C. Krauss(Schneider Children's Medical Center), Sarah Lawson(Boston Children's Hospital), Eric Bachman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yoshiyuki Takahashi(Nagoya University), David Bueno(Hospital Universitario La Paz)
Cited by 0
Related Papers
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term<i>In vitro</i>Culture and Do Not Exhibit Telomere Maintenance Mechanisms
|Cancer Research|2007|702
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
|Journal of Clinical Oncology|2015|383
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
|New England Journal of Medicine|2016|348